Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Lubiprostone

Brand: Amitiza®
NICE TA: 318
Indication: Treating chronic idiopathic constipation (NICE TA318)
Disease category: Gastro-intestinal system
Commissioning responsibility: CCG
PbR excluded: No

Background

Lubiprostone (Amtizia®) is recommended as an option for treating chronic idiopathic constipation (adults in whom treatment with at least 2 laxatives from different classes, at the highest tolerated recommended doses for at least 6 months, has failed to provide adequate relief and for whom invasive treatment for constipation is being considered). If treatment with lubiprostone is not effective after 2 weeks, the person should be re-examined and the benefit of continuing treatment reconsidered. Lubiprostone should only be prescribed by a clinician with experience of treating chronic idiopathic constipation, who has carefully reviewed the person’s previous courses of laxative treatments specified in 1.1

Recommendation

LMMG recommendation: Amber0
Click here to find the definitions for the colour classifications

Reason for decision:  Suitable for GP prescribing following recommendation/initiation by specialist

Supporting documents:

NICE TA318 Lubiprostone for treating chronic idiopathic constipation

Constipation Pathway (Version 1.2) (665.1 KiB)

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Amber0

Amber 0

Red

Amber0